ASTRO 2017: Updates in HPV-Positive Head and Neck Cancer

Video
Conference|American Society for Radiation Oncology Annual Meeting (ASTRO)

This video highlights studies on HPV-positive head and neck cancer presented at the 2017 ASTRO Annual Meeting.

In this video, David Raben, MD, of the University of Colorado Cancer Center, highlights selected studies on the treatment of HPV-positive head and neck cancer presented at the 2017 American Society for Radiation Oncology (ASTRO) Annual Meeting, held September 24–27 in San Diego.

Raben was the discussant for a head and neck cancer session that featured the following abstracts:

• Quantification of HPV-16 in circulating tumor DNA during de-intensified chemoradiotherapy for favorable-risk HPV-associated oropharyngeal squamous cell carcinoma (abstract 92)

• Induction chemotherapy followed by concurrent chemoradiation vs concurrent chemoradiation alone in the definitive management of p16-positive oropharyngeal cancer with low-neck or N3 disease (abstract 93)

• Nodal radiographic prognostic factors in the new stage I p16-positive oropharyngeal cancer of the AJCC 8th edition: is all N1 disease the same? (abstract 293)

• Long-term survival in oligometastatic head and neck cancer (abstract 296)

Recent Videos
The phase 3 NIVOSTOP trial evaluated an anti–PD-1 immunotherapy, nivolumab, in a patient population similar in the KEYNOTE-689 trial.
Opportunities to further reduce relapses include pembrolizumab-based combination therapy and evaluating the agent’s contribution before and after surgery.
For patients with locally advanced head and neck cancers, the current standard of care for curative therapy has a cure rate of less than 50%.
Patrick Oh, MD, highlights next steps for further research in treating patients with systemic therapy in addition to radiotherapy for early-stage NSCLC.
Increased use of systemic therapies, particularly among patients with high-risk node-negative NSCLC, were observed following radiotherapy.
Heather Zinkin, MD, states that reflexology improved pain from chemotherapy-induced neuropathy in patients undergoing radiotherapy for breast cancer.
A prospective trial may help affirm ctDNA as a non-invasive option of predicting responses to radiotherapy among those with gynecologic cancers.
Interest in novel therapies to improve outcomes initiated an investigation of the use of immunotherapy in early-stage non-small cell lung cancer.
ctDNA reductions or clearance also appeared to correlate with a decrease in disease burden during the pre-boost phase of radiotherapy.
Related Content
Data from the phase 3 KEYNOTE-689 trial support the approval of the pembrolizumab-based regimen in this locally advanced HNSCC population.

FDA Approves Perioperative Pembrolizumab Plus Radiation in HNSCC

Russ Conroy
June 12th 2025
Article

Data from the phase 3 KEYNOTE-689 trial support the approval of the pembrolizumab-based regimen in this locally advanced HNSCC population.

David Sher on the Updated ASTRO Guidelines for Oropharyngeal Cancer

David Sher on the Updated ASTRO Guidelines for Oropharyngeal Cancer

David J. Sher, MD, MPH
September 15th 2017
Podcast

In this interview we discuss new clinical guidelines from ASTRO on the use of radiotherapy in treating oropharyngeal cancer.

From breast cancer to head and neck tumors, the 2025 ASCO Annual Meeting may feature a wide range of practice-changing data across cancer care.

ASCO 2025: The Presentations That May Shift the Cancer Care Paradigm

Russ Conroy
May 23rd 2025
Article

From breast cancer to head and neck tumors, the 2025 ASCO Annual Meeting may feature a wide range of practice-changing data across cancer care.

Efti plus pembrolizumab demonstrated no new safety signals in the TACTI-003 trial.

Frontline Efti Combo Yields Meaningful Survival in PD-L1–Low HNSCC

Russ Conroy
May 8th 2025
Article

Survival data with eftilagimod alfa plus pembrolizumab compare favorably with historical results seen with standard-of-care therapies in this population.

Event-free survival events were observed in 37.5% of patients taking pembrolizumab vs 45.3% without among patients with resectable locally advanced HNSCC.

Perioperative Pembrolizumab Enhances Survival in Locally Advanced HNSCC

Ashley Chan
April 30th 2025
Article

Event-free survival events were observed in 37.5% of patients with resectable locally advanced HNSCC who took pembrolizumab vs 45.3% in those who did not.

Data from the phase 3 AK105-304 study support the approval of penpulimab in this nasopharyngeal carcinoma population.

FDA Approves Penpulimab in Non-Keratinizing Nasopharyngeal Carcinoma

Roman Fabbricatore
April 24th 2025
Article

Data from the phase 3 AK105-304 study support the approval of penpulimab in this nasopharyngeal carcinoma population.